IN
INmune Bio, Inc.
INMB · NASDAQ
$2.03 +2.53% (+$0.05)
1M -11.74%
Market Cap $54.0M
P/E Ratio -
Div. Yield -
ROE 82.87%
Bulios Fair Price
$1.73
14.8% downside
Current Price
$2.03
Undervalued Fair Value Overvalued
According to Bulios Fair Price, INMB is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
1/9Valuation
72 /100
Cheap P/B 2.65x
PEG N/A
P/E N/A
Growth
0 /100
Declining Book val. growth 26.85%
Rev. growth 48.87%
FCF growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 68.60%
ROIC 92.78%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 4.04x
Debt/Equity 0.07x
Debt/Assets N/A
Stability
52 /100
Moderate EPS volatility 19.16%
Beta 0.94x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about INMB
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David J. Moss
Employees
21
Headquarters
Boca Raton
Upcoming events
29 OCT
Earnings
Upcoming earnings report